Recombinant human FVIIa for reducing the need for invasive second‐line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial

Authors :: Lavigne‐Lissalde, G.
Aya, A.G.
Mercier, F.J.
Roger‐Christoph, S.
Chauleur, C.
Morau, E.
Ducloy‐Bouthors, A.S.
Mignon, A.
Raucoules, M.
Bongain, A.
Boehlen, F.
de Moerloose, P.
Bouvet, S.
Fabbro‐Peray, P.
Gris, J.‐C.
Source :: Journal of Thrombosis and Haemostasis; April 2015, Vol. 13 Issue: 4 p520-529, 10p
Publication Year :: 2015
Abstract: Case reports on recombinant human factor VIIa (rhuFVIIa) use in women with severe postpartum hemorrhage (PPH) showed encouraging results, but no randomized controlled trial (RCT) is available.

Full Text Access

Tools